Last reviewed · How we verify
durvalumab and vactosertib
At a glance
| Generic name | durvalumab and vactosertib |
|---|---|
| Sponsor | Hark Kyun Kim |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC (PHASE1, PHASE2)
- Vactosertib and Durvalumab in Gastric Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- durvalumab and vactosertib CI brief — competitive landscape report
- durvalumab and vactosertib updates RSS · CI watch RSS
- Hark Kyun Kim portfolio CI